Generics Catch A Break With Hikma's Skinny Label Win
By Dani Kass · January 6, 2022, 10:26 PM EST
Generic-drug makers have spent more than a year voicing concerns that the Federal Circuit's holding in GlaxoSmithKline v. Teva threatened their ability to sell generic drugs that leave patent-protected indications off...
To view the full article, register now.